- Five years, two products: is the EU's advanced therapies legislation working?
- uniQure hands Chiesi European Glybera marketing rights
- BioNotebook: Tonix, XenoPort offerings; Ophthotech royalty financing; UniQure, Achaogen IPOs
- EMA under attack again over document disclosure
COMMENT Other Informa Comment
- Leadership lesson: How to slim down and shape up, Kress style
- The man behind Vertex’s quest to conquer cystic fibrosis: Jeffrey Leiden